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Abstract
Background: Because chronic obstructive pulmonary disease (COPD) is a heterogeneous condition, the identification of
specific clinical phenotypes is key to developing more effective therapies. To explore if the persistence of systemic
inflammation is associated with poor clinical outcomes in COPD we assessed patients recruited to the well-characterized
ECLIPSE cohort (NCT00292552).
Methods and Findings: Six inflammatory biomarkers in peripheral blood (white blood cells (WBC) count and CRP, IL-6, IL-8,
fibrinogen and TNF-a levels) were quantified in 1,755 COPD patients, 297 smokers with normal spirometry and 202 non-
smoker controls that were followed-up for three years. We found that, at baseline, 30% of COPD patients did not show
evidence of systemic inflammation whereas 16% had persistent systemic inflammation. Even though pulmonary
abnormalities were similar in these two groups, persistently inflamed patients during follow-up had significantly increased
all-cause mortality (13% vs. 2%, p,0.001) and exacerbation frequency (1.5 (1.5) vs. 0.9 (1.1) per year, p,0.001) compared to
non-inflamed ones. As a descriptive study our results show associations but do not prove causality. Besides this, the
inflammatory response is complex and we studied only a limited panel of biomarkers, albeit they are those investigated by
the majority of previous studies and are often and easily measured in clinical practice.
Conclusions: Overall, these results identify a novel systemic inflammatory COPD phenotype that may be the target of
specific research and treatment.
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Introduction
Non Communicable Diseases (NCDs), including cardiovascular
diseases, chronic respiratory diseases, cancer and diabetes, are the
major global health problem of the century [1]. They are the
world leading cause of disease burden and mortality, are
increasing in prevalence even in low- and middle-income
countries, the costs incurred by uncontrolled NCDs are substan-
tial, and they are an under-appreciated cause of poverty and
hinder economic development [2]. Chronic obstructive pulmonary
disease (COPD) is the major respiratory NCD [2,3]. It affects
around 10% of the adult population [4], and it is predicted that it
will be the third cause of death and disability in the world by the
year 2020 [5].
Persistent, low-level, systemic inflammation is thought to play a
significant pathogenic role in many NCDs including COPD [6].
Elevated circulating levels of white blood cells (WBC), C-reactive
protein (CRP), interleukins 6 (IL-6) and 8 (IL-8), fibrinogen and
tumor necrosis factor alpha (TNFa) have been reported in patients
with COPD [7–9]. However, most previous studies were small and
cross-sectional, showed large variability between patients, did not
consider the effects of potential confounders, such as smoking
status and treatment with anti-inflammatory agents and, impor-
tantly, did not investigate their relationship with relevant clinical
outcomes of the disease.
The inflammatory response is a complex network of many
different cells and molecules [10,11]. Addressing this complexity is
a key challenge for a better understanding and treatment of NCDs
in general [2], and COPD in particular [12,13]. The emerging
field of network medicine provides a platform to explore the
complexity of apparently distinct phenotypes of a disease [14].
Because COPD is a complex disease with pulmonary and extra-
pulmonary manifestations [15], the identification and prospective
validation of specific clinical phenotypes is key for the develop-
ment of novel and more effective therapies [16]. We hypothesized
that the persistence of systemic inflammation in COPD constitutes
a novel COPD phenotype [16] because it does not occur in all
COPD patients but, when persistently present, it is associated with
worse clinical outcomes. To test this hypothesis, we determined in
1755 COPD patients, 297 smokers and 202 non-smoker controls
included in the ECLIPSE study [17]: (1) the prevalence, temporal
stability and network pattern (inflammome [18]) of the six
inflammatory biomarkers most often studied in COPD (WBC
count, CRP, IL-6, IL-8, fibrinogen and TNFa) [8,9]; and, (2) their
relationship with clinical characteristics and relevant outcomes at 3
years follow-up. Our results support that the presence of persistent
systemic inflammation constitutes a novel COPD phenotype.
Methods
Study Design and Ethics
The design and methods of the ECLIPSE study (Clinicaltrials.-
gov identifier NCT00292552; GSK study code SCO104960) have
been published previously [17]. Briefly, ECLIPSE is an observa-
tional, longitudinal study in which, after the baseline visit,
participants are evaluated at 3 months, 6 months and then every
6 months for 3 years. ECLIPSE complies with the Declaration of
Helsinki and Good Clinical Practice Guidelines, and has been
approved by the ethics committees/institutional review boards of
the participating centers (listed in Information S1). All participants
provided written informed consent.
Population
We recruited into the ECLIPSE study 2164 patients with
COPD, 337 smoking and 245 non-smoking controls [15]. COPD
patients were male/female subjects aged 40–75 yrs., with a
baseline post-bronchodilator Forced Expiratory Volume in 1 sec.
(FEV1) ,80% of the reference value, an FEV1/Forced Vital
Capacity (FVC) ratio #0.7 and a current or former smoking
history of $10 pack-yrs., who did not report a COPD
exacerbation within the 4 weeks that preceded enrollment [17].
Controls were healthy male/female subjects aged 40–75 yrs. with
normal spirometry; smoker controls were current or ex-smokers
with a smoking history $10 pack-yrs. whereas nonsmoking
controls had a smoking history of ,1 pack-yrs. In the current
analysis we included only those subjects with complete data for the
six biomarkers analyzed (1755 COPD patients (81% of the COPD
patients recruited into ECLIPSE), 297 smokers with normal lung
function (88%) and 202 non-smokers (83%)).
Measurements
The methodology used in the ECLIPSE study has been
published at length elsewhere [15,17]. Briefly, validated question-
naires were used to record clinical data and nutritional status was
assessed as the body mass index (BMI) and fat-free mass index
(FFMI), the latter measured by bioelectrical impedance [15,17].
Exacerbations in the year prior to the study and during follow up
were recorded as reported elsewhere [19]. Spirometry and the 6
minute walking distance (6MWD) were performed according to
international guidelines [20,21]. The European Community for
Coal and Steel Spirometric reference values were used [22]. The
BODE index was calculated as previously described [23]. Low-
dose computed tomography (CT) scan of the chest (GE Healthcare
or Siemens Healthcare) [15,17] was obtained; the percentage of
lung CT voxels ,2950 Hounsfield Units was used to quantify
level of emphysema (Pulmonary Workstation 2.0. VIDA Diag-
nostics, Iowa City, IA, USA) [24].
Of particular interest for the current study are the biomarker
measurements. To this end, peripheral venous blood was collected
into Vacutainer tubes, in the morning, after fasting overnight, at
baseline and at the one year follow-up visit. Circulating WBC
count was measured in a central clinical laboratory. Serum was
prepared by centrifugation of whole blood at 1500 g for 10 to15
minutes and plasma (EDTA as the anticoagulant) was obtained by
centrifugation at 2000 g for 10 to 15 minutes. Samples were stored
at –80u until analyzed centrally. IL-6, IL-8 and TNF-a serum
concentrations were determined by validated immunoassays
(SearchLight Array Technology, Thermo Fisher Scientific, Rock-
ford, IL, USA), whereas CRP (Roche Diagnostics, Mannheim,
Germany) and fibrinogen (K-ASSAY fibrinogen test, Kamiya
Biomedical Co., Seattle, WA, USA) levels were measured using
immunoturbidometric assays validated for use with EDTA plasma.
The lower limit of quantification (LLQ) for IL-6, IL-8, TNF-a,
CRP and fibrinogen were 0.4 pg/mL, 0.8 pg/mL, 4.7 pg/mL,
0.02 mg/mL, and 5.4 mg/dL, respectively. Biomarker concentra-
tions were below the LLQ in some individuals. To avoid a
downward bias of the population data, a nominal level of half of
the LLQ value was used in the analysis in individuals with values
below the LLQ [25].
Statistical Analysis
Results are shown as mean (SD), median values [interquartile
range [IQR]], frequency distribution (quartiles) or proportions, as
appropriate. Because none of the continuous variables were
The Systemic Inflammatory COPD Phenotype
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37483
T
a
b
le
1
.
M
e
an
(S
D
),
m
e
d
ia
n
[I
Q
R
],
o
r
p
ro
p
o
rt
io
n
o
f
th
e
m
ai
n
ch
ar
ac
te
ri
st
ic
s
o
f
th
e
th
re
e
g
ro
u
p
s
o
f
p
ar
ti
ci
p
an
ts
at
b
as
e
lin
e
.
P
-v
a
lu
e
s
C
O
P
D
S
u
b
je
ct
s
(N
=
1
7
5
5
)
S
m
o
k
e
r
C
o
n
tr
o
ls
(N
=
2
9
7
)
N
o
n
-s
m
o
k
e
r
C
o
n
tr
o
ls
(N
=
2
0
2
)
O
v
e
ra
ll
C
O
P
D
S
u
b
je
ct
s
v
s
S
m
o
k
e
r
C
o
n
tr
o
ls
C
O
P
D
S
u
b
je
ct
s
v
s
N
o
n
-
sm
o
k
e
r
C
o
n
tr
o
ls
S
m
o
k
e
r
C
o
n
tr
o
ls
v
s
N
o
n
-s
m
o
k
e
r
C
o
n
tr
o
ls
D
e
m
o
g
ra
p
h
ic
s
A
g
e
(y
rs
.)
6
3
.5
(7
.1
)
5
5
.5
(8
.8
)
5
3
.0
(8
.6
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
0
.0
0
2
M
al
e
(%
)
1
1
6
0
(6
6
%
)
1
6
2
(5
5
%
)
7
6
(3
8
%
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
C
u
rr
e
n
t
sm
o
ke
r
(%
)
6
4
0
(3
6
%
)
1
8
7
(6
3
%
)
0
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
Sm
o
ki
n
g
,
p
ac
k-
ye
ar
s
4
8
.9
(2
7
.1
)
3
1
.7
(2
2
.1
)
0
.2
(1
.2
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
B
M
I,
kg
/m
2
2
6
.5
(5
.6
)
2
6
.7
(4
.6
)
2
7
.7
(5
.5
)
0
.0
1
7
N
S
0
.0
0
6
N
S
FF
M
I,
kg
/m
2
1
7
.2
(2
.9
)
1
7
.0
(2
.6
)
1
7
.3
(2
.7
)
N
S
N
S
N
S
N
S
C
h
ro
n
ic
b
ro
n
ch
it
is
(%
)
5
9
9
(3
4
%
)
2
9
(1
0
%
)
3
(1
%
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
m
M
R
C
Sc
o
re
1
.7
(1
.1
)
0
.2
(0
.5
)
0
.1
(0
.4
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
0
.0
0
1
SG
R
Q
-C
T
o
ta
l
Sc
o
re
4
9
.6
(2
0
.1
)
9
.4
(1
1
.9
)
5
.0
(6
.7
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
Ex
ac
e
rb
at
io
n
ra
te
(P
ri
o
r
Y
e
ar
)
0
.8
(1
.2
)
0
.0
(0
.0
)
0
.0
(0
.0
)
IC
S
U
se
(%
)
1
2
5
3
(7
1
%
)
3
(1
%
)
0
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
N
S
C
ar
d
io
va
sc
u
la
r
d
is
e
as
e
(%
)
5
7
7
(3
3
%
)
4
5
(1
5
%
)
3
1
(1
5
%
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
N
S
St
at
in
U
se
(%
)
3
9
6
(2
3
%
)
4
8
(1
6
%
)
2
5
(1
2
%
)
,
0
.0
0
1
0
.0
1
3
,
0
.0
0
1
N
S
P
h
y
si
o
lo
g
y
a
n
d
Im
a
g
in
g
FE
V
1
/F
V
C
,
%
4
4
.6
(1
1
.4
)
7
9
.1
(5
.1
)
8
1
.4
(5
.2
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
FE
V
1
(L
)
1
.3
5
(0
.5
2
)
3
.3
1
(0
.7
5
)
3
.3
4
(0
.7
9
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
N
S
FE
V
1
%
P
re
d
ic
te
d
4
8
.2
(1
5
.6
)
1
0
8
.8
(1
2
.1
)
1
1
5
.3
(1
4
.2
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
FE
V
1
re
ve
rs
ib
ili
ty
,
%
1
0
.9
(1
3
.8
)
4
.4
(5
.9
)
2
.6
(4
.0
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
6
M
W
D
,
m
3
7
1
(1
2
1
)
B
O
D
E
In
d
e
x
3
.1
(2
.1
)
%
LA
A
o
n
C
T
(,
2
9
5
0
H
U
)
1
7
.6
(1
2
.2
)
2
.4
(3
.1
)
3
.9
(3
.9
)
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
In
fl
a
m
m
a
to
ry
B
io
m
a
rk
e
rs
W
h
it
e
B
lo
o
d
C
e
lls
(X
1
0
6
/m
l)
7
.6
[6
.3
,9
.0
]
7
.1
[6
.1
,8
.6
]
5
.8
[5
.0
,7
.0
]
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
H
ig
h
Se
n
si
ti
vi
ty
C
R
P
(m
g
/l
)
3
.2
[1
.5
,7
.1
]
1
.6
[0
.8
,3
.3
]
1
.3
[0
.6
,2
.7
]
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
0
.0
4
1
IL
-6
(p
g
/m
l)
1
.5
[0
.8
,3
.1
]
0
.6
[0
.3
,1
.3
]
0
.4
[0
.2
,0
.9
]
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
IL
-8
(p
g
/m
l)
6
.9
[3
.2
,1
3
.3
]
7
.8
[3
.8
,1
4
.2
]
4
.3
[2
.3
,7
.2
]
,
0
.0
0
1
0
.0
1
3
,
0
.0
0
1
,
0
.0
0
1
Fi
b
ri
n
o
g
e
n
(m
g
/d
l)
4
4
8
.0
[3
8
8
.0
,5
1
7
.0
]
3
9
1
.0
[3
4
8
.0
,4
3
6
.0
]
3
6
9
.0
[3
2
6
.0
,4
3
2
.0
]
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
0
.0
0
3
T
N
F-
al
p
h
a
(p
g
/m
l)
2
.3
5
[2
.3
5
,7
.8
0
]
2
.3
5
[2
.3
5
,4
0
.7
0
]
2
.3
5
[2
.3
5
,2
.3
5
]
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
,
0
.0
0
1
N
S:
n
o
n
-s
ig
n
if
ic
an
t.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
3
7
4
8
3
.t
0
0
1
The Systemic Inflammatory COPD Phenotype
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37483
normally distributed, Kruskal-Wallis tests were used to analyze the
statistical significance of differences between groups. Differences in
categorical variables were assessed using Cochran-Mantel-Haens-
zel tests. Logistic regression was used to investigate factors
contributing to persistent systemic inflammation in patients with
COPD. P-values less than 0.05 (two sided) were considered
significant.
Results
Demographics and Clinical Data
Table 1 presents the main demographic and clinical character-
istics of all participants at recruitment. On average, COPD
patients had moderate to severe airflow limitation and, as
expected, complained of more symptoms, exacerbations and
cardiovascular disease than controls. Non-smokers and smokers
without COPD had normal spirometry and were slightly younger
than the COPD patients. There were a higher proportion of
females among controls.
Cross-sectional Analysis of Systemic Inflammation at
Recruitment
Figure 1 shows a box plot of the six inflammatory biomarkers
measured at recruitment in the three groups of subjects studied,
and Table 1 shows their median [IQR] values. Despite large
variability within each group (note the logarithmic scale on
Figure 1) and relatively small absolute differences between groups
(Table 1), on average the WBC count and levels of CRP, IL-6 and
fibrinogen were significantly higher in COPD patients than in
smokers with normal lung function and nonsmokers, whereas IL-8
and TNFa values were higher in smokers without COPD (Figure 1,
Table 1). CRP, IL-6 and fibrinogen were not influenced by active
smoking, and WBC counts were only slightly higher in current
smokers compared with former smokers and non-smokers (Table
S1). In patients with COPD, the WBC count and the serum levels
of CRP, IL-6 and fibrinogen, but not those of IL-8 and TNFa,
tended to increase with the severity of airflow limitation (Table
S2).In absolute terms, differences in the levels of systemic
biomarkers between GOLD stages were small and often not
consistent between stages (Table S2).
To determine the prevalence of elevated inflammatory
biomarkers, values .95th percentile of healthy non-smokers were
considered abnormal [26,27] (Table S3). Seventy seven percent of
non-smokers, 42% of smokers and, importantly, 30% of COPD
patients did not have any abnormal biomarker, so defined. Figure
S1 shows that the percentage of individuals with abnormal
biomarker values was significantly shifted towards the right (more
inflammation) in smokers (vs. nonsmokers), and more so in
patients with COPD (vs. smokers and nonsmokers).
Figure 2 presents a network layout of the systemic inflammatory
pattern in the three groups of participants. Each node of the
network represents one biomarker, its size being proportional to
the percentage of abnormal values (exact figure shown inside) in
each group. Nodes are linked if 1% or more of subjects share
abnormal values for the particular biomarkers, and the width of
the link represents the size of this percentage. In non-smokers,
nodes are, by definition, small but, interestingly, links are rare and
thin, indicating the virtual absence of an inflammome (Figure 2).
In smokers with normal spirometry, some nodes (WBC, IL-8 and
TNFa) are larger (p,0.001) than in nonsmokers whereas others
(CRP, IL-6 and fibrinogen) have a similar size (p = ns), and a
network (inflammome) is now clearly visible, with many thick
linking lines (Figure 2). In patients with COPD, the network is
further developed (more and thicker links) with some nodes (WBC
Figure 1. Box plot (log scale) of the different biomarkers determined at baseline in COPD patients, smokers with normal lung
function and nonsmokers. For further explanations, see text.
doi:10.1371/journal.pone.0037483.g001
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(p,0.03), CRP (p,0.001), IL-6(p,0.001) and fibrinogen
(p,0.001)) increasing, and others (IL-8 (p,0.02) and TNFa
(p,0.001)) decreasing in size as compared with smokers with
normal lung function (Figure 2). This pattern was maintained
when current smokers with normal spirometry were compared
with former smokers with COPD (Figure S2). Because IL-8 and
TNFa appear to be primarily markers of smoking and not of
COPD (Table S1, and Figures 2 and S2), we excluded them from
further analysis.
Longitudinal Stability of Systemic Inflammation
Figure 3 shows the proportion of COPD patients with zero, one
and two (or more) biomarkers (WBC, CRP, IL-6 and fibrinogen)
in their upper quartile distribution determined at baseline and one
year later (Table S4). At recruitment (left bars), 28% of the COPD
patients had two or more biomarkers in the upper quartile, and
this was still the case for 56% of these individuals one year later
(right-top bars). Overall, subjects with 2 or more biomarkers in the
upper quartile both at baseline and after one year represent 16%
of the population of patients studied (Figure 3).In contrast, 43% of
COPD patients did not have any biomarker in the upper quartile
of their distribution and this remained true for 70% of these
subjects one year later (right-bottom bars). These subjects
correspond to 30% of the total population studied. Their
proportion decreased with the GOLD stage of airflow limitation
whereas that of persistently inflamed patients increased slightly
(Figure S3).The systemic inflammome determined at baseline was
stable for the four biomarkers analyzed at one year follow-up in
each group of participants (Figure S4).
Relationship between Systemic Inflammation, Disease
Characteristics and Clinical Outcomes
Table 2 compares the baseline demographics, clinical, func-
tional and imaging characteristics of the patients with (2+ elevated
biomarker levels) and without (none) persistent (at baseline and 1
year later) systemic inflammation. Age and gender were similar in
both groups, but patients with persistent systemic inflammation
were more obese, had slightly more cumulative exposure to
smoking and were more likely to be current smokers, were more
symptomatic, had worse health status, reported a higher preva-
lence of COPD exacerbations and cardiovascular disease and a
higher proportion used inhaled steroids, but not statins. Airflow
limitation was slightly worse in these patients, as were their
exercise tolerance and BODE index, but neither the prevalence of
chronic bronchitis, nor the degree of airflow limitation reversibility
or the extent of CT- emphysema were different between the two
groups (Table 2). Table 3 presents the results of the logistic
regression analysis for persistent systemic inflammation in COPD.
Age, BMI (but not FFMI, suggesting a role for adipose tissue),
current smoking, health status and airflow limitation were
associated with increased risk of persistent, systemic inflammation.
Interestingly, gender, cumulative smoking exposure, presence of
chronic bronchitis, prior exacerbation rate, use of ICS, history of
cardiovascular disease, statin use, exercise tolerance and the
Figure 2. Network layout of the systemic inflammatory response (inflammome) in non-smokers (n=202), smokers with normal lung
function (n=297) and COPD patients (n =1755) at recruitment. Each node of the network corresponds to one of the six inflammatory
biomarkers determined in this study (see color code), and its size is proportional to the prevalence of abnormal values (.95th percentile of non-
smokers) of that particular biomarker in that particular group of subjects (precise figure shown inside of each node). Two nodes are linked if more
than 1% of subjects in the network share abnormal values of these two biomarkers, its width being proportional to that proportion. For further
explanations, see text.
doi:10.1371/journal.pone.0037483.g002
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presence of emphysema were not associated with the presence of
persistent systemic inflammation in COPD (Table 3).
During the three year follow up, both all-cause mortality (13%
vs. 2%, p,0.001) and the annual rate of COPD exacerbations
(adjusted for prior exacerbation rate (1.5 (1.5) vs. 0.9 (1.1),
p,0.001) [19]) were significantly higher in individuals with
persistent systemic inflammation compared with those without it.
By contrast, neither the rate of FEV1 decline (233646 vs.
233643 ml/yr., p = 0.905), weight loss (21.3 (6.7) vs. 20.7 (5.5)
Kg, p = 0.504) or the occurrence of new cardiovascular events (7%
vs. 9%, p= 0.500) were significantly different between these two
groups.
Discussion
This study provides three relevant and novel observations. First,
it characterizes the systemic inflammatory network pattern
(inflammome) in patients with COPD and distinguishes it from
that of smokers with normal lung function and non-smokers.
Secondly, it shows that systemic inflammation is not a constant
feature in all COPD patients, since about a third of those studied
here did not have any abnormal biomarker at baseline and about
the same proportion remained ‘non-inflamed’ after one year of
follow up. Finally, it identifies a subgroup of COPD patients with
persistently elevated inflammatory biomarker levels that, despite
relatively similar lung function impairment, had significantly
increased all-cause mortality and exacerbation frequency. These
inflamed patients may therefore constitute a novel distinct
phenotype within the larger group of patients with COPD and
could be the target of novel therapeutic strategies.
Several studies have previously reported elevated levels of
circulating WBC, CRP, IL-6, IL-8, fibrinogen and TNFa in
patients with clinically stable COPD [8,28–37]. Yet, they were
limited because of the relatively small numbers of patients studied,
the large variability of values observed, the fact that measurements
were mostly made on a single occasion, potential confounders such
as smoking status and treatment with anti-inflammatory drugs
were not considered and, importantly, the longitudinal relation-
ship with relevant clinical outcomes of the disease could not be
established because of their cross-sectional design. Our study
overcomes these limitations and provides, therefore, novel
information on the true prevalence of systemic inflammation in
COPD and its importance in the progression of disease.
The inflammatory response is a complex network of multiple
cell types and mediators [10,11] which the emerging field of
network medicine is only beginning to decipher [14,38]. We used
this approach [2,12,13]to identify relationships between systemic
inflammatory biomarkers (the inflammome) [18] among smokers
with and without COPD. We recognize that our results are
incomplete but they showed that, at variance with current
understanding [7–9], systemic inflammation is not a constant
feature of COPD and that, when present for at least 1 year, it is
associated with worse COPD outcomes at 3 years follow-up. Age,
gender and smoking exposure were similar between non-inflamed
and inflamed patients but the latter were more obese, dyspneic,
had lower health related quality of life, more frequent exacerba-
tions, worse exercise tolerance, a higher BODE index and
reported more cardiovascular disease, despite similar use of statins
(Table 2). Interestingly, although airflow limitation was slightly
worse in patients with persistent inflammation, most pulmonary
characteristics of COPD, such as the prevalence of chronic
Figure 3. Proportion of patients with none, one, or two (or more) biomarkers (WBC count, CRP, IL-6 and fibrinogen) in the upper
quartile of the COPD distribution, at baseline (left bars) and after one year follow up (right bars). For further explanations, see text.
doi:10.1371/journal.pone.0037483.g003
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bronchitis, the degree of emphysema, the bronchodilator response
and the rate of FEV1 decline during follow-up, were similar in
both groups (Table 2). Logistic regression analysis identified age,
BMI, current smoking, health status and airflow limitation as risk
factors for persistent inflammation whereas gender, cumulative
smoking exposure, presence of chronic bronchitis, prior exacer-
bation rate, use of ICS, history of cardiovascular disease, statin
use, exercise tolerance and the presence of emphysema were
excluded (Table 3). Taken together, these observations suggest that
systemic inflammation in COPD need not parallel the severity of
the lung disease and raises questions about its pulmonary origin
(the ‘‘spill-over’’ hypothesis) [9]. In contrast, the fact that
persistently inflamed patients were more obese supports a potential
systemic origin of inflammation [39], although other potential
mechanisms, such as the presence of airway bacterial colonization
[40] and/or sleep apnea syndrome overlap [41] cannot be
excluded because they were not investigated in ECLIPSE. The
origin of systemic inflammation in COPD remains to be
determined. However, our findings are consistent with those of
Garcia-Aymerich et al, who using a different methodological
approach (cluster analysis) also identified a ‘‘systemic’’ COPD
subtype characterized by more systemic inflammation and a
higher proportion of obesity in 342 COPD patients followed
during 4 years [42].
An important observation of our study is that all-cause mortality
(13% vs. 2%) and the annual rate of moderate/severe COPD
exacerbations (1.5 vs. 0.9 per year) during the 3 year follow-up
were higher (p,0.001) in the persistently inflamed patients,
compared with non-inflamed patients. These observations are
clinically relevant because the severity of airflow limitation has
been used so far as the most important criteria to guide therapy in
COPD [43], whereas our study shows that patients with similar
levels of airflow limitation may have different outcomes depending
on the presence or absence of persistent systemic inflammation.
Indeed, a persistent elevation of systemic inflammatory biomarkers
can occur even in patients with moderate airflow limitation (Figure
S3). In this context, it is worth noting that among the 220 patients
identified in this study with persistent systemic inflammation
(Table 2), 89 (40%) were frequent exacerbators according to the
definition of Hurst et al [19], an additional 61 (28%) had a single
exacerbation, and the remaining 70 (32%) reported no exacerba-
tions during the first year of follow up, suggesting that the frequent
exacerbator phenotype [19] and the persistently inflamed pheno-
type described here are not necessarily identifying the same
individuals. Finally, given the limited efficacy of inhaled cortico-
steroids in reducing systemic inflammation in COPD [44], patients
with persistent systemic inflammation may require a different
therapeutic approach for the optimal management of their disease
that will have to be explored in future studies.
Our study has several strengths and limitations. To date, it
provides the largest longitudinal investigation of systemic inflam-
matory biomarkers in a group of stable, well characterized COPD
patients and compares their results to those of smoking and non-
smoking controls [17]. This latter aspect proved important for the
Table 2. Comparison of baseline demographics, clinical, physiological and imaging characteristics of COPD patients with none or
two (or more) biomarker levels in the upper quartile of the COPD distribution both at baseline and at one year follow-up.
Number of Biomarkers Elevated at Both Visits
0, N=431 (30%) 2+, N =220 (16%) p-value
Demographics and clinical data
Age (yrs.) 63.2 (6.9) 64.5 (6.5) 0.03
Male (%) 276 (64%) 152 (69%) NS
BMI, kg/m‘2 25.6 (4.8) 29.4 (7.3) ,0.001
FFMI, kg/m‘2 16.9 (2.6) 18.3 (3.9) ,0.001
Smoking, pack-years 44.2 (24.2) 54.7 (31.6) ,0.001
Current smoker (%) 133 (31%) 88 (40%) 0.02
Chronic Bronchitis (%) 123 (29%) 78 (35%) NS
mMRC Score 1.3 (0.9) 2.0 (1.1) ,0.001
SGRQ-C Total Score 42.3 (19.1) 56.8 (19.8) ,0.001
Exacerbation rate (Prior Year) 0.7 (1.2) 1.1 (1.5) ,0.001
ICS Use (%) 284 (66%) 174 (79%) ,0.001
Cardiovascular disease (%) 113 (26%) 80 (36%) 0.007
Statin Use (%) 96 (22%) 56 (25%) NS
Physiology and Imaging
FEV1 (L) 1.49 (0.53) 1.26 (0.44) ,0.001
FEV1% Predicted 52.6 (15.2) 46.0 (14.5) ,0.001
FEV1 reversibility, % 11.4 (14.8) 11.7 (13.7) NS
FEV1/FVC, % 46.1 (11.1) 44.5 (10.9) NS
6MWD, m 419 (109) 336 (117) ,0.001
BODE Index 2.3 (1.8) 3.8 (2.0) ,0.001
%LAA on CT (,2950HU) 17.3 (12.4) 16.8 (10.1) NS
NS: non-significant.
doi:10.1371/journal.pone.0037483.t002
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proper interpretation of the findings reported here, since the large
biomarker variability observed required the establishment of
upper normal values. Likewise, given the significant effect of
smoking identified, any accurate interpretation of abnormal levels
of inflammatory markers in COPD must take it into account. The
fact that patients were followed prospectively for 3 years is another
strength of our study because it not only allowed the assessment of
the temporal stability of the biomarker levels but, importantly, the
investigation of their relationship with clinically relevant outcomes,
and thus the identification of a distinct subgroup of COPD
patients with worse clinical outcomes associated with the
persistence of systemic inflammation. Our study also has some
potential limitations. First, this is a descriptive study, so our results
only show associations and do not prove causality. Besides, since
this is an exploratory analysis, we opted to identify as many
possible differences for further investigation by not adjusting for
multiple comparisons. Hence, our analyses and conclusions will
need to be replicated either prospectively in a study powered for
these hypotheses or in other cohorts that contain similar data.
Second, the biology of the inflammatory response is complex and
we studied only a limited panel of biomarkers. However, the
biomarkers we chose correspond to those investigated by the
majority of previous studies [8,28–33] and are often and easily
measured in clinical practice. Yet, we did not study markers of
tissue repair, and it is likely that the balance between inflammation
and repair is important for the pathobiology of COPD [45].
Third, patients were recruited into ECLIPSE mostly from hospital
clinics and were treated according to their local physician. These
considerations need to be taken into account when comparing
results with untreated patients or patients managed in primary
care since no patients with mild airflow limitation (GOLD grade 1)
were included in the study. Finally, mortality data refers to all-
cause mortality since cause-specific mortality was not recorded in
the study.
In conclusion, this study begins to describe the systemic
inflammatory network pattern (inflammome) associated with
COPD and how it differs from that of smokers with normal lung
function. It also identifies a sub-group of COPD patients with
persistently increased biomarkers levels that is associated with a
higher incidence of exacerbations and worse survival despite
similar lung impairment, suggesting that this constitutes a novel
COPD phenotype [16]. Future clinical trials will have to
determine the best therapeutic strategy for these patients. This
may have important therapeutic implications also for other major
non-communicable diseases, including cardiovascular and meta-
bolic diseases, also characterized by chronic low-level systemic
inflammation [7,46].
Supporting Information
Figure S1 Frequency distribution of the percentage of
individuals in each group with none, one or more
abnormal biomarker values (.95th percentile of the
nonsmoker controls) at baseline. For further explanations,
see text.
(TIF)
Figure S2 Systemic inflammome of non-smokers
(n=202), current smokers (only) with normal lung
function (n=187) and former-smokers (only) with COPD
Table 3. Summary of logistic regression for persistent systemic inflammation (defined as in upper quartile at both visits for at least
2 biomarkers).
Odds Ratio (95% CI) p-value AUC for Model
0.76
Demographics and clinical data
Age (yrs.) 1.045 (1.014, 1.077) 0.004
Female vs. Male 0.645 (0.383, 1.085) 0.098
BMI, kg/m2 1.125 (1.063, 1.190) ,0.001
Fat free mass index, kg/m2 0.979 (0.866, 1.106) 0.728
Current smoker vs. Former smoker 2.228 (1.471, 3.375) ,0.001
Smoking, pack-years 1.004 (0.997, 1.011) 0.217
Chronic bronchitis 0.929 (0.624, 1.384) 0.717
mMRC Dyspnea Score 0.949 (0.756, 1.191) 0.65
SGRQ-C Total Score 1.017 (1.004, 1.030) 0.012
Exacerbation rate (prior year) 1.097 (0.956, 1.260) 0.187
ICS Use 1.354 (0.850, 2.159) 0.202
Cardiovascular disease 0.714 (0.470, 1.085) 0.114
Statin Use 0.899 (0.576, 1.403) 0.638
Physiology and imaging
FEV1% Predicted 0.975 (0.956, 0.995) 0.014
FEV1 Reversibility 0.999 (0.987, 1.011) 0.841
FEV1/FVC (%) 1.000 (0.972, 1.028) 0.977
6MWD (m) 0.998 (0.997, 1.000) 0.13
%LAA 0.987 (0.965, 1.008) 0.219
Statistically significant factors are highlighted in bold. For further explanations, see text.
doi:10.1371/journal.pone.0037483.t003
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(n =1115) at baseline. IL-8 and TNFa are very much
influenced by current smoking whereas hs-CRP, IL-6 and
fibrinogen are COPD-related inflammatory biomarkers. WBC
counts are influenced both by smoking and COPD. For further
explanations, see text.
(TIF)
Figure S3 Percentage of COPD patients, by GOLD stage
of airflow limitation severity, with none (blue bars) or 2+
biomarkers (red bars) in the upper quartile of the COPD
distribution of values both at baseline and after one year
follow-up. For further discussion, see text.
(TIF)
Figure S4 Systemic inflammome of the four biomarkers
analyzed at baseline (upper panels) and at one year
follow-up (bottom panels) in the same individuals in
each group (note the same n value). Differences between
groups were maintained after one year follow-up but were
basically non-existent within groups, indicating stability of the
systemic inflammome in each group. For further explanations, see
text.
(TIF)
Table S1 Median [IQR] of the inflammatory biomark-
ers determined at baseline in COPD patients and
smokers with normal lung function by smoking status.
(DOCX)
Table S2 Median [IQR] of the inflammatory biomark-
ers determined at baseline in COPD patients by GOLD
stages of airflow limitation.
(DOCX)
Table S3 95th percentile values of the six biomarkers
determined in healthy non-smokers at baseline. For
further explanations, see text.
(DOCX)
Table S4 Summary of 75th percentile value of the four
biomarkers determined in COPD patients both at
baseline and one year later. For further explanations, see text.
(DOCX)
Information S1 Members of the ECLIPSE Steering and
Scientific Committees. ECLIPSE Study Investigators and
Study Centre Locations.
(DOCX)
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